Adenoviral Vectors for Gene Therapy

ISBN-13: 9780128002766 / Angielski / Twarda / 2016 / 868 str.

David T. Curiel

Opis

Adenoviral Vectors for Gene Therapy, Second Edition provides detailed, comprehensive coverage of the gene delivery vehicles that are based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, making gene therapy a fast-growing field for research. This book presents topics ranging from the basic biology of adenoviruses, through the construction and purification of adenoviral vectors, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models, with final consideration of the regulatory issues surrounding human clinical gene therapy trials. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.

• Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors
• Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement
• Demonstrates noninvasive imaging of adenovirus-mediated gene transfer
• Discusses utility of adenoviral vectors in animal disease models
• Considers Federal Drug Administration regulations for human clinical trials

Spis treści

1. Adenovirus Structure 2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms 3. Adenovirus Replication 4. Adenoviral Vector Construction I: Mammalian Systems 5. Adenoviral Vector Construction II: Bacterial Systems 6. Upstream Bioprocess for Adenovirus Vectors 7. Propagation of Adenoviral Vectors: Use of PER.C6T Cells 8. Purification of Adenovirus 9. Targeted Adenoviral Vectors I: Transductional Targeting 10. Targeted Adenoviral Vectors III: Transcriptional Targeting 11. Adenoviral Vector Targeting via Mitigation of Liver Sequestration 12. Molecular Design of Oncolytic Adenoviruses 13. Conditionally Replicative Adenoviruses-Clinical Trials 14. Innate Immune Response to Adenovirus Vector Administration In Vivo 15. Antibodies against Adenoviruses 16. Methods to Mitigate Immune Responses to Adenoviral Vectors 17. Helper-Dependent Adenoviral Vectors 18. Hybrid Adenoviral Vectors 19. Xenogenic Adenoviral Vectors 20. Engineering Chimeric Adenoviruses: Exploiting Virus Diversity for Improved Vectors, Vaccines, and Oncolytics 1. Introduction 22. Adenoviral Vectors Vaccine: Capsid Incorporation of Antigen 23. Utility of Adenoviral Vectors in Animal Models of Human Disease I: Cancer 24. In Situ Vaccination with Adenoviral Vectors to Treat Cancer 25. Utility of Adenoviral Vectors in Animal Models of Human Disease II: Genetic Disease 26. Adenoviral Vectors for Pulmonary Disease (Pulmonary Vascular Disease) 27. Utility of Adenoviral Vectors in Animal Models of Human Disease III: Acquired Diseases 28. Animal Models of Gene Therapy for Cardiovascular Disease 29. Polymer-Anchored Adenovirus as a Therapeutic Agent for Cancer Gene Therapy 30. Adenoviral Vectors for RNAi Delivery 31. Imaging and Adenoviral Gene Therapy 32. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective

O autorze

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel's scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.